SCHEMBL1129782

SCHEMBL1129782

CCN(CC)c1ccc(/C=N\NC(=O)c2ccc(O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 1.00
ALDH1A1 P00352 10/20 1.00
ESRRG P62508 7/20 1.00
KDM4E B2RXH2 7/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
HPGD P15428 3/20 1.00
TP53 P04637 2/20 1.00
CYP3A4 P08684 1/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
CASP1 P29466 1/20 1.00
HSD17B10 Q99714 1/20 1.00
HDAC6 Q9UBN7 1/20 1.00
GAA P10253 4/20 0.65
GLA P06280 1/20 0.65
GFER P55789 1/20 0.65
LMNA P02545 3/20 0.64
POLB P06746 2/20 0.64
RAB9A P51151 6/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131315 1.00 MAPT (1.00) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL1131313 1.00 MAPT (1.00) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL15315413 0.88 MAPT (0.79) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL15315410 0.88 ESRRG (1.00) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL15315409 0.87 MAPT (0.77) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL2536737 0.86 MAPT (0.76) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL8243886 0.86 MAPT (0.76) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL12443591 0.86 ESRRG (0.77) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL15315412 0.85 ESRRG (1.00) MAPTALDH1A1ESRRGKDM4EMEN1
SCHEMBL9755109 0.85 ESRRG (1.00) MAPTALDH1A1ESRRGKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12599665-B2 Gene fusions for control of genetically modified cells A2 BIOTHERAPEUTICS, INC. (US) 2026-04-14 US disclosed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US disclosed
CN-115851745-B Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease 河南省人民医院 2023-10-27 CN disclosed
US-20230330227-A1 GENE FUSIONS FOR CONTROL OF GENETICALLY MODIFIED CELLS A2 BIOTHERAPEUTICS, INC. 2023-10-19 US disclosed
CN-115851745-A Application of substance for regulating Esrrb activity in preparation of product for intervening retinoschisis 河南省人民医院 2023-03-28 CN disclosed
US-20180207114-A1 ESTROGEN RELATED RECEPTOR GAMMA (ERRgamma) ENHANCES AND MAINTAINS BROWN FAT THERMOGENIC CAPACITY SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-07-26 US disclosed
US-20180207114-A1 ESTROGEN RELATED RECEPTOR GAMMA (ERRgamma) ENHANCES AND MAINTAINS BROWN FAT THERMOGENIC CAPACITY SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-07-26 US disclosed
US-20180015057-A1 ERR ALPHA AND ERR GAMMA ARE ESSENTIAL COORDINATORS OF CARDIAC METABOLISM AND FUNCTION SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-01-18 US disclosed
US-20180015057-A1 ERR ALPHA AND ERR GAMMA ARE ESSENTIAL COORDINATORS OF CARDIAC METABOLISM AND FUNCTION SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-01-18 US disclosed
US-20170189485-A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-07-06 US disclosed
US-8962546-B2 Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2015-02-24 US disclosed
US-20120302491-A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2012-11-29 US disclosed
US-20120302491-A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2012-11-29 US disclosed
US-20110165570-A1 METHOD OF EFFECTING DE-DIFFERENTIATION OF A CELL AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-07-07 US disclosed
EP-2283118-A1 METHOD OF EFFECTING DE-DIFFERENTIATION OF A CELL Agency for Science, Technology And Research (SG) 2011-02-16 EP disclosed
EP-2015777-B1 USE OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-18 EP disclosed
US-20090281191-A1 USE OF ORGANIC COMPOUNDS RANGWALA SHAMINA M 2009-11-12 US disclosed
WO-2009136867-A1 METHOD OF EFFECTING DE-DIFFERENTIATION OF A CELL AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-11-12 WO disclosed
EP-2015777-A2 USE OF ORGANIC COMPOUNDS Novartis AG (CH) 2009-01-21 EP disclosed
WO-2007131005-A2 USE OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302491-A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR ESRRA, ESRRB, ESRRG MAPT 4589/4885ALDH1A1 1305/4885ESRRG 3/4885
US-20170189485-A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR ESRRA, ESRRB, ESRRG MAPT 4589/4885ALDH1A1 1305/4885ESRRG 3/4885
US-20230330227-A1 GENE FUSIONS FOR CONTROL OF GENETICALLY MODIFIED CELLS BAX, TIAL1, CCAR2 MAPT 4371/4885ALDH1A1 4556/4885ESRRG 190/4885
US-20180207114-A1 ESTROGEN RELATED RECEPTOR GAMMA (ERRgamma) ENHANCES AND MAINTAINS BROWN FAT THERMOGENIC CAPACITY ESRRG, ESRRA, ESRRB MAPT 2782/4885ALDH1A1 730/4885ESRRG 1/4885
US-12599665-B2 Gene fusions for control of genetically modified cells BID, ESR1, BCLAF1 MAPT 911/4885ALDH1A1 4643/4885ESRRG 28/4885
US-20090281191-A1 USE OF ORGANIC COMPOUNDS GPR119, PPARG, NR1H2 MAPT 244/4885ALDH1A1 826/4885ESRRG 6/4885
US-20180015057-A1 ERR ALPHA AND ERR GAMMA ARE ESSENTIAL COORDINATORS OF CARDIAC METABOLISM AND FUNCTION ESRRA, ESRRB, ESRRG MAPT 3895/4885ALDH1A1 1155/4885ESRRG 3/4885
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME SQSTM1, BECN1, CUTA MAPT 411/4885ALDH1A1 4219/4885ESRRG 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.